2 min read

Ubiquitin, protein degradation, and cancer drugs

Hershko, Ciechanover, and Rose showed how cells label selected proteins with ubiquitin and send them to the proteasome for breakdown. Later research on this pathway helped enable proteasome-inhibiting drugs, including bortezomib.

Miriam Bernstein

Miriam Bernstein is the pen name of Hasbara’s Resources desk. Articles on this desk are written and published automatically by artificial intelligence, with no person reviewing them before publication.

Avram Hershko, Aaron Ciechanover, and Irwin Rose discovered that cells can mark selected proteins with ubiquitin and direct them to the proteasome for destruction. Their 2004 Nobel Prize recognized this basic cellular mechanism; later work on the proteasome led to medicines such as bortezomib.

How the ubiquitin tag works

Ubiquitin is a small protein of 76 amino acids. Enzymes attach it to a target protein; repeated attachment creates a signal recognized by the proteasome, a large protein complex that breaks the target into peptides. The process allows cells to control the timing and amount of particular proteins, including proteins involved in cell-cycle regulation, DNA repair, and protein quality control. The Nobel Prize summary describes the tagging and degradation pathway.

Hershko and Ciechanover conducted key work at the Technion in Haifa, collaborating with Rose at Fox Chase Cancer Center in Philadelphia. Their 1980 papers identified the ATP-dependent system and its components. The prize was shared equally among all three scientists, and its official citation was “for the discovery of ubiquitin-mediated protein degradation.” Ciechanover’s Nobel profile documents the collaboration and research.

From cell biology to treatment

The discovery established a target for subsequent drug research. Bortezomib inhibits proteasome activity and became an important treatment for multiple myeloma. The connection is a research pathway developed over years: the prize-winning discovery explained the cell’s regulated degradation system, while later studies tested how disrupting proteasome function could treat cancer. Proteasome inhibition also affects healthy cells, so the drug is not a tumor-only switch. The U.S. National Cancer Institute’s drug record identifies bortezomib and its clinical use.

Why the mechanism matters

Cells use controlled protein removal alongside protein production. The ubiquitin system helps regulate signaling and remove damaged or unnecessary proteins. Hershko, Ciechanover, and Rose’s work supplied a molecular explanation for selective degradation and opened a defined research field in cell regulation and disease. For the broader roster, see Israeli and Israel-linked Nobel laureates in science.

Sources

  1. 1.https://www.nobelprize.org/prizes/chemistry/2004/summary/
  2. 2.https://www.nobelprize.org/prizes/chemistry/2004/ciechanover/facts/
  3. 3.https://www.cancer.gov/about-cancer/treatment/drugs/bortezomib

Accessibility

These settings are saved on this device.

Preview

Read clearly, your way

Adjust this page while you read. Explore resources

Text
Text sizeApplies across the site.
Colour and contrast
Theme
Motion
AnimationsMatch device follows your reduced motion setting.